Press Releases

GlobeNewswire, Inc.

NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Thursday, November 12, 2026, featuring live webcast presentations from international...

GlobeNewswire, Inc.

TORONTO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, will release its third...

GlobeNewswire, Inc.

New York, USA, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Company sets out the full label, sales terms and safety information for its coffee sachet in each of its four main markets Wellaray, the dietary supplement company that makes Wellaray Slim Coffee...

EIN Presswire

The Business Research Company’s Blood Bank Information Systems Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 LONDON, GREATER LONDON, UNITED KINGDOM, November 6, 2026 /⁨EINPresswire.com⁩/ -- The blood bank information...

GlobeNewswire, Inc.

KIMMTRAK® (tebentafusp-tebn) net revenues of $102.2 million in Q3 2026 and net revenues of $324.8 million for the first nine months of 2026, representing 10% year-over-year growth year to date Phase 3 TEBE-AM trial for previously treated advanced...

GlobeNewswire, Inc.

RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its third quarter 2026...

GlobeNewswire, Inc.

LONG BEACH, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- SkinHealth Systems Inc. (NASDAQ: SKIN) (“SkinHealth Systems” or the "Company"), home to flagship brand Hydrafacial®, today announced financial results for the third quarter ended September 30,...

GlobeNewswire, Inc.

Third Quarter Revenue of $31.7 Million, an Increase of 9.4%; Net Income of $1.9 Million, an Increase of 305%; and Adjusted EBITDA of $7.9 Million, an Increase of 95% Playboy Signs Agreement to Acquire Property for Future Membership Club in Miami...

GlobeNewswire, Inc.

Received authorization in the United Kingdom and European Union to expand global first-in-human ASCEND Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP1-related disorder, adding to clearances in Australia and Argentina Company remains...

GlobeNewswire, Inc.

Advancing a pipeline built entirely on the Alector Brain Carrier (ABC) blood-brain barrier platform, spanning antibody, enzyme, and siRNA programs, with AL137, Alector's lead ABC-enabled anti-amyloid beta (Aβ) antibody program for Alzheimer's...

GlobeNewswire, Inc.

Adjusted EBITDA1 up 14% to $438 million, with margin expanding to 10.3% from 9.4%, led by high-protein dairy ingredients.

GlobeNewswire, Inc.

In a release issued under the same headline on Thursday, November 5th by Altus Group Limited (TSX: AIF), please note that in the table in the Business Outlook Section, and under Implied AR $ and Revenues for FY 2026, the number should be 457.5...

GlobeNewswire, Inc.

Steady revenue growth and adjusted EBITDA margin* expansion Four consecutive quarters of double-digit software Annual Recurring Revenue* (“ARR”) growth TORONTO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Altus Group Limited (ʺAltus Group”, “Altus” or “the...

GlobeNewswire, Inc.

Q3 2026 revenue of $32.9 million; GAAP basic EPS: $(0.04) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed SAN DIEGO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre, Gyre Therapeutics or the Company) (Nasdaq:...

GlobeNewswire, Inc.

Adult and adolescent cohorts fully enrolled in registrational SAFEGUARD study of SAB-142; Pediatric cohort (ages 5–11) actively enrolling with overall enrollment on track for completion in Q4 2026 Received FDA Fast Track designation for SAB-142 in...

GlobeNewswire, Inc.

Phase 3 SONATA-HCM study substantially overenrolled; top-line data expected Q1 2027 Positive STENO1 safety data strengthens benefit-risk profile for ZYNQUISTA® NDA resubmission Phase 1 clinical development of LX9851 ongoing by Novo Conference call...

GlobeNewswire, Inc.

CLYM116 Phase 1 data in healthy volunteers showed sustained >90% free APRIL suppression and ~70% Gd-IgA1 reduction at 12 weeks after a single dose, supporting every-12-week dosing Initiated dosing in NAVIGATE-2 Phase 2 trial of CLYM116 in IgAN;...

GlobeNewswire, Inc.

Q3 2026 EPS Exceeded the Guidance, Both Revenue and GM In-Line With Guidance Issued on Aug. 6, 2026 Company Q4 2026 Guidance: Revenues to Decrease 22% to 26%, Gross Margin is Expected to be Flat to Slightly up. Profit per Diluted ADS to be 4.5...

EIN Presswire

SYDNEY, AUSTRALIA, November 5, 2026 /⁨EINPresswire.com⁩/ -- DDP Property, an Australian residential and commercial property services firm, has released an analysis of how the Reserve Bank of Australia's 2026 rate cycle is affecting borrowers,...

GlobeNewswire, Inc.

PERTH, Australia, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Perth, Australia - Paladin Energy Ltd (ASX:PDN, TSX:PDN, OTCQX:PALAF) (“Paladin” or the “Company”) advises that it has released its unaudited Condensed Interim Financial Report and Management’s...